DRTG(600329.SH)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
DRTG
600329.SH
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited and changed its name to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in May 2022. The company was founded in 1915 and is based in Tianjin, the People’s Republic of China.
2.805 T
600329.SHMarket value -Rank by Market Cap -/-

Financial Score

20/05/2026 Update
C
PharmaceuticalsIndustry
Industry Ranking71/215
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE27.71%A
    • Profit Margin43.81%A
    • Gross Margin77.71%A
  • Growth ScoreE
    • Revenue YoY-25.45%E
    • Net Profit YoY-1.61%C
    • Total Assets YoY-6.56%D
    • Net Assets YoY-8.51%D
  • Cash ScoreD
    • Cash Flow Margin24.20%D
    • OCF YoY-25.45%E
  • Operating ScoreC
    • Turnover0.46C
  • Debt ScoreB
    • Gearing Ratio27.92%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Ultra-high dividend yield stocks exposed, 47 stocks with the latest dividend yield exceeding 5%

    36Kr·
    SH
    600329
    -3.18%
    SH
    600690
    -0.48%
    SZ
    002763
    -1.25%
    36Kr·
    SH
    600329
    -3.18%
    SH
    600690
    -0.48%
    SZ
    002763
    -1.25%

    With only six months left until July 1, 2026, the implementation of Article 75 of the National Medical Products Administration's "Special Regulations on the Registration of Traditional Chinese Medicine" is entering its final window period. This regulation, referred to in the industry as the "death clause" for proprietary Chinese medicines, clearly states that after three years of implementation starting from July 1, 2023, the contraindications in the instructions will be prohibited

    Wallstreetcn·
    SH
    512290
    -0.11%
    SZ
    159929
    -0.71%
    SH
    600436
    -0.77%
    Wallstreetcn·
    SH
    512290
    -0.11%
    SZ
    159929
    -0.71%
    SH
    600436
    -0.77%

    TJ DaRenTang announced its semi-annual performance, with a net profit attributable to the parent company of 1.928 billion yuan, a year-on-year increase of 193.08%

    Zhitong·
    SH
    600329
    -3.18%
    SG
    T14
    +1.86%
    Zhitong·
    SH
    600329
    -3.18%
    SG
    T14
    +1.86%

    Some traditional Chinese medicine stocks saw their net profits double year-on-year in the first half of the year

    Zhitong·
    SH
    600671
    -0.16%
    SH
    600329
    -3.18%
    SZ
    000623
    -1.12%
    Zhitong·
    SH
    600671
    -0.16%
    SH
    600329
    -3.18%
    SZ
    000623
    -1.12%

    TJ DaRenTang: Tongmai Yangxin Pills strongly recommended in the Traditional Chinese Medicine Diagnosis and Treatment Guidelines for Coronary Microvascular Disease

    Zhitong·
    SH
    600329
    -3.18%
    SG
    T14
    +1.86%
    Zhitong·
    SH
    600329
    -3.18%
    SG
    T14
    +1.86%
    © 2026 Longbridge｜Disclaimer